|
Source – Druginfozone - Findings reported at the 57th annual meeting of the American Academy of Neurology, reports that tetrabenazine is an effective and well-tolerated treatment for severe hyperkinetic movement disorders among children who are resistant to other medication.
The study involved the treatment of 30 children aged 18 years and younger with tetrabenazine. These children had a variety of
hyperkinetic movement disorders, including chorea, dystonia, and Tourette Syndrome or tics. A retrospective chart review was conducted over the course of 18 years to assess the efficacy and tolerability
of tetrabenazine among these patients. Twenty-eight patients (93%) had tried other medications without adequate relief prior to being placed on tetrabenazine. On average, patients were treated with a
total dose of 150.9 mg/d (4.9 mg/kg/d) for 1.3 years
For more information go to: http://www.druginfozone.nhs.uk/record%20viewing/viewRecord.aspx?id=54801 9
Prepared by Susan Wileman Medicines Information Technician
Date of Preparation: 18th April 2005
|
